ReviewFrontiers in oncology2021

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials.

Lisha Mou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.